IGM Biosciences 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
birinapant (IGM-9427) / IGM Biosciences
NCT03809208: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
1
34
US
Birinapant, Intensity modulated re-irradiation therapy (IMMRT)
National Cancer Institute (NCI)
Head Cancer, Facial Cancer, Neck Cancer, Upper AerodigestiveTract Cancer, Oral Cancer
10/20
10/21
NCT03803774: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
13
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Birinapant, TL32711, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
11/23
03/26
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
01/25
01/25
imvotamab (IGM-2323) / IGM Biosciences
IGM-2323-001, NCT04082936 / 2021-002339-44: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Hourglass Jan 2022 - Dec 2022 : Initial data from trial for DLBCL/follicular lymphoma
Hourglass Jan 2021 - Dec 2021 : Completion of enrollment of P1 trial for NHL
Checkmark Safety and efficacy data from trial for r/r NHL at ASH 2021
Dec 2021 - Dec 2021: Safety and efficacy data from trial for r/r NHL at ASH 2021
Checkmark Interim data from trial for r/r NHL at ASH 2020
More
Terminated
1/2
97
Europe, US, RoW
imvotamab
IGM Biosciences, Inc., ADC Therapeutics S.A.
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
02/24
02/24
IGM-2323-103, NCT06524687: A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

Terminated
1
2
US
Imvotamab
IGM Biosciences, Inc.
Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
01/25
01/25
IGM-2323-102, NCT06087406: A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Terminated
1
33
Europe, US
Imvotamab, Placebo
IGM Biosciences, Inc.
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
02/25
02/25
IGM-2323-101, NCT06041568: A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Terminated
1
17
Europe, US, RoW
Imvotamab
IGM Biosciences, Inc.
Systemic Lupus Erythematosus, Lupus Erythematosus
01/25
01/25
NCT06331832: Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

No Longer Available
N/A
Europe, RoW
IGM2323
IGM Biosciences, Inc.
Relapsed/Refractory Non-Hodgkin Lymphomas
 
 
IGM-7354 / IGM Biosciences
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Completed
1
14
US
IGM-7354
IGM Biosciences, Inc.
Solid Tumor
05/24
05/24
IGM-2644 / IGM Biosciences
NCT05908396: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Terminated
1
4
US
IGM-2644
IGM Biosciences, Inc.
Multiple Myeloma
02/24
02/24
Undisclosed IgM based bispecific antibody / IGM Biosciences
No trials found
Undisclosed cancer therapeutic / Sanofi, IGM Biosciences
No trials found
Anti-OX40 IgM agonist antibody / IGM Biosciences
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
birinapant (IGM-9427) / IGM Biosciences
NCT03809208: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
1
34
US
Birinapant, Intensity modulated re-irradiation therapy (IMMRT)
National Cancer Institute (NCI)
Head Cancer, Facial Cancer, Neck Cancer, Upper AerodigestiveTract Cancer, Oral Cancer
10/20
10/21
NCT03803774: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
13
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Birinapant, TL32711, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
11/23
03/26
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
01/25
01/25
imvotamab (IGM-2323) / IGM Biosciences
IGM-2323-001, NCT04082936 / 2021-002339-44: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Hourglass Jan 2022 - Dec 2022 : Initial data from trial for DLBCL/follicular lymphoma
Hourglass Jan 2021 - Dec 2021 : Completion of enrollment of P1 trial for NHL
Checkmark Safety and efficacy data from trial for r/r NHL at ASH 2021
Dec 2021 - Dec 2021: Safety and efficacy data from trial for r/r NHL at ASH 2021
Checkmark Interim data from trial for r/r NHL at ASH 2020
More
Terminated
1/2
97
Europe, US, RoW
imvotamab
IGM Biosciences, Inc., ADC Therapeutics S.A.
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
02/24
02/24
IGM-2323-103, NCT06524687: A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

Terminated
1
2
US
Imvotamab
IGM Biosciences, Inc.
Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
01/25
01/25
IGM-2323-102, NCT06087406: A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Terminated
1
33
Europe, US
Imvotamab, Placebo
IGM Biosciences, Inc.
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
02/25
02/25
IGM-2323-101, NCT06041568: A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Terminated
1
17
Europe, US, RoW
Imvotamab
IGM Biosciences, Inc.
Systemic Lupus Erythematosus, Lupus Erythematosus
01/25
01/25
NCT06331832: Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

No Longer Available
N/A
Europe, RoW
IGM2323
IGM Biosciences, Inc.
Relapsed/Refractory Non-Hodgkin Lymphomas
 
 
IGM-7354 / IGM Biosciences
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Completed
1
14
US
IGM-7354
IGM Biosciences, Inc.
Solid Tumor
05/24
05/24
IGM-2644 / IGM Biosciences
NCT05908396: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Terminated
1
4
US
IGM-2644
IGM Biosciences, Inc.
Multiple Myeloma
02/24
02/24
Undisclosed IgM based bispecific antibody / IGM Biosciences
No trials found
Undisclosed cancer therapeutic / Sanofi, IGM Biosciences
No trials found
Anti-OX40 IgM agonist antibody / IGM Biosciences
No trials found

Download Options